# Regeneron Pharmaceuticals, Inc. (REGN) — Q4-2012 Earnings Results

**Report date:** 2013-02-14 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q4-2012

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Down 0.64%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.47 | N/A | +37.38% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, they did not provide specific guidance for future quarters.

**Key quotes:**

> We are pleased with our EPS performance this quarter.

> Our focus remains on innovation and expanding our product pipeline.

### Guidance Changes

No forward guidance was provided in this earnings report.

### What It Means

Regeneron's strong EPS performance indicates effective cost management and profitability, despite the lack of revenue data. The stock's slight decline of 0.64% may reflect investor caution due to the absence of guidance. Overall, the company appears to be on a solid footing but will need to provide more clarity in future reports to reassure investors.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q4-2012_